Medical diagnostics firm Biomerica's Q2 revenue falls amid product transition

Reuters

Jan 15

Medical diagnostics firm Biomerica's <a href="https://laohu8.com/S/QTWO">Q2</a> revenue falls amid product transition

Overview

Medical diagnostics firm's Q2 revenue fell yr/yr due to absence of large distributor orders
Net loss for Q2 widened to $1.32 mln from $0.95 mln last year
Company entered marketing agreement with Henry Schein for inFoods IBS test

Outlook

Biomerica sees incremental revenue from inFoods IBS and new partnerships driving margin expansion
Company expects Medicare payment rate to expand patient access to inFoods IBS
Biomerica plans to leverage regulatory approval in Egypt for international expansion

Result Drivers

PRODUCT TRANSITION - Biomerica is shifting focus from lower-margin products to higher-margin diagnostic-guided therapy products, impacting current revenue
MENA REGION ORDERS - Revenue decline attributed to absence of large initial distributor orders in MENA region
COST MANAGEMENT - Operating expenses decreased by 4% year-to-date due to cost discipline and operational efficiency

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Revenue		$1.21 mln
Q2 Net Income		-$1.32 mln
Q2 Gross Margin		4.00%
Q2 Operating Expenses		$1.42 mln
Q2 Operating Income		-$1.37 mln

Press Release: ID:nGNX2y46Vp

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2603408076"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603408076\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603408076?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-15 06:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603408076","market":"nz","top_or_hot":-1,"title":"Medical diagnostics firm Biomerica's Q2 revenue falls amid product transition","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Medical diagnostics firm Biomerica's <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue falls amid product transition</title></head><body><p><span>Overview</span></p><ul><li><p>Medical diagnostics firm's Q2 revenue fell yr/yr due to absence of large distributor orders</p></li><li><p>Net loss for Q2 widened to $1.32 mln from $0.95 mln last year</p></li><li><p>Company entered marketing agreement with Henry Schein for inFoods IBS test</p></li></ul><p><span>Outlook</span></p><ul><li><p>Biomerica sees incremental revenue from inFoods IBS and new partnerships driving margin expansion</p></li><li><p>Company expects Medicare payment rate to expand patient access to inFoods IBS</p></li><li><p>Biomerica plans to leverage regulatory approval in Egypt for international expansion</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>PRODUCT TRANSITION - Biomerica is shifting focus from lower-margin products to higher-margin diagnostic-guided therapy products, impacting current revenue</p></li><li><p>MENA REGION ORDERS - Revenue decline attributed to absence of large initial distributor orders in MENA region</p></li><li><p>COST MANAGEMENT - Operating expenses decreased by 4% year-to-date due to cost discipline and operational efficiency</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Revenue</p></td><td></td><td><p>$1.21 mln</p></td><td></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>-$1.32 mln</p></td><td></td></tr><tr><td><p>Q2 Gross Margin</p></td><td></td><td><p>4.00%</p></td><td></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$1.42 mln</p></td><td></td></tr><tr><td><p>Q2 Operating Income</p></td><td></td><td><p>-$1.37 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nGNX2y46Vp</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medical diagnostics firm Biomerica's Q2 revenue falls amid product transition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedical diagnostics firm Biomerica's Q2 revenue falls amid product transition\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-15 06:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Medical diagnostics firm Biomerica's <a href=\"https://laohu8.com/S/QTWO\">Q2</a> revenue falls amid product transition</title></head><body><p><span>Overview</span></p><ul><li><p>Medical diagnostics firm's Q2 revenue fell yr/yr due to absence of large distributor orders</p></li><li><p>Net loss for Q2 widened to $1.32 mln from $0.95 mln last year</p></li><li><p>Company entered marketing agreement with Henry Schein for inFoods IBS test</p></li></ul><p><span>Outlook</span></p><ul><li><p>Biomerica sees incremental revenue from inFoods IBS and new partnerships driving margin expansion</p></li><li><p>Company expects Medicare payment rate to expand patient access to inFoods IBS</p></li><li><p>Biomerica plans to leverage regulatory approval in Egypt for international expansion</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>PRODUCT TRANSITION - Biomerica is shifting focus from lower-margin products to higher-margin diagnostic-guided therapy products, impacting current revenue</p></li><li><p>MENA REGION ORDERS - Revenue decline attributed to absence of large initial distributor orders in MENA region</p></li><li><p>COST MANAGEMENT - Operating expenses decreased by 4% year-to-date due to cost discipline and operational efficiency</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Revenue</p></td><td></td><td><p>$1.21 mln</p></td><td></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>-$1.32 mln</p></td><td></td></tr><tr><td><p>Q2 Gross Margin</p></td><td></td><td><p>4.00%</p></td><td></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$1.42 mln</p></td><td></td></tr><tr><td><p>Q2 Operating Income</p></td><td></td><td><p>-$1.37 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nGNX2y46Vp</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BMRA","symbol_name":"Biomerica Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nL1N3YF18U:1","article_id":"2603408076","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603408076","pubTimestamp":1768429802,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Medical diagnostics firm Biomerica's Q2 revenue falls amid product transitionOverviewMedical diagnostics firm's Q2 revenue fell yr/yr due to absence of large distributor ordersNet loss for Q2 widened ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BMRA":"Biomerica Inc","BK4082":"医疗保健设备"},"translate_title":"医疗诊断公司Biomerica第二季度收入因产品转型而下降","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMRA":0.9},"content_text":"Medical diagnostics firm Biomerica's Q2 revenue falls amid product transitionOverviewMedical diagnostics firm's Q2 revenue fell yr/yr due to absence of large distributor ordersNet loss for Q2 widened to $1.32 mln from $0.95 mln last yearCompany entered marketing agreement with Henry Schein for inFoods IBS testOutlookBiomerica sees incremental revenue from inFoods IBS and new partnerships driving margin expansionCompany expects Medicare payment rate to expand patient access to inFoods IBSBiomerica plans to leverage regulatory approval in Egypt for international expansionResult DriversPRODUCT TRANSITION - Biomerica is shifting focus from lower-margin products to higher-margin diagnostic-guided therapy products, impacting current revenueMENA REGION ORDERS - Revenue decline attributed to absence of large initial distributor orders in MENA regionCOST MANAGEMENT - Operating expenses decreased by 4% year-to-date due to cost discipline and operational efficiencyKey DetailsMetricBeat/MissActualConsensus EstimateQ2 Revenue$1.21 mlnQ2 Net Income-$1.32 mlnQ2 Gross Margin4.00%Q2 Operating Expenses$1.42 mlnQ2 Operating Income-$1.37 mlnPress Release: ID:nGNX2y46VpFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}